UBS AM
MIRM icon

UBS AM’s Mirum Pharmaceuticals MIRM Stock Holding History

UBS AM’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.05M Buy
68,725
+2,096
+3% +$210K ﹤0.01% 1371
2026
Q1 		$6.16M Buy
66,629
+7,428
+13% +$699K ﹤0.01% 1462
2025
Q4 		$4.68M Sell
59,201
-1,498
-2% -$108K ﹤0.01% 1497
2025
Q3 		$4.45M Sell
60,699
-100,791
-62% -$6.41M ﹤0.01% 1428
2025
Q2 		$8.22M Buy
161,490
+11,972
+8% +$533K ﹤0.01% 1455
2025
Q1 		$6.74M Buy
149,518
+75,630
+102% +$3.56M ﹤0.01% 1410
2024
Q4 		$3.06M Buy
73,888
+10,427
+16% +$435K ﹤0.01% 1842
2024
Q3 		$2.47M Buy
63,461
+3,442
+6% +$137K ﹤0.01% 1931
2024
Q2 		$2.05M Buy
60,019
+18,914
+46% +$496K ﹤0.01% 1984
2024
Q1 		$1.03M Buy
41,105
+300
+0.7% +$8.25K ﹤0.01% 1998
2023
Q4 		$1.2M Buy
40,805
+1,995
+5% +$60.4K ﹤0.01% 1926
2023
Q3 		$1.23M Buy
38,810
+15,961
+70% +$437K ﹤0.01% 1849
2023
Q2 		$549K Hold
22,849
– – ﹤0.01% 2283
2023
Q1 		$549K Buy
22,849
+2,685
+13% +$61.2K ﹤0.01% 2283
2022
Q4 		$393K Buy
+20,164
New +$399K ﹤0.01% 2265

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's MIRM Position: Q2 2026 in Review

UBS AM increased its Mirum Pharmaceuticals (MIRM) stake by 3.1% in Q2 2026, buying an estimated $210K and bringing the position to 68,725 shares worth $8.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

UBS AM first reported a position in MIRM in Q4 2022 and has held it in 15 quarters since. The position peaked at $8.22M in Q2 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • UBS AM held 68,725 shares of Mirum Pharmaceuticals worth $8.05M as of Q2 2026.
  • UBS AM bought 2,096 Mirum Pharmaceuticals shares in Q2 2026, an estimated $210K.
  • Mirum Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1371 holding.
  • UBS AM first reported a position in Mirum Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • UBS AM's Mirum Pharmaceuticals position peaked at $8.22M in Q2 2025.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.